Terms ending in 2029
Every in-force patent on Codexis, Inc.'s record whose computed term ends in 2029, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 8,088,610 | Ketoreductases for the Production of (S,E)-Methyl 2-(3-(3-(2-(7-Chloroquinolin-2-YL)VINYL)PHENYL)-3-Hroxypropyl)BENZOATE In force · High confidence | Codexis, Inc. | In force | High confidence | |
| US 9,139,820 | Ketoreductase Polypeptides In force · High confidence | Codexis, Inc. | In force | High confidence | |
| US 9,422,530 | Ketoreductase Polypeptides In force · High confidence | Codexis, Inc. | In force | High confidence | |
| US 9,796,964 | Ketoreductase Polypeptides In force · High confidence | Codexis, Inc. | In force | High confidence | |
| US 10,246,687 | Ketoreductase Polypeptides In force · High confidence | Codexis, Inc. | In force | High confidence | |
| US 10,544,401 | Ketoreductase Polypeptides In force · High confidence | Codexis, Inc. | In force | High confidence | |
| US 10,988,739 | Ketoreductase Polypeptides In force · High confidence | Photon Valley, Inc. | In force | High confidence | |
| US 8,673,607 | Ketoreductase Polypeptides for the Production of a 3-ARYL-3 Hydroxypropanamine from a 3-ARYL-3-Ketopropanamine In force · High confidence | Codexis, Inc. | In force | High confidence | |
| US 9,228,213 | Polynucleotides Encoding Engineered Ketoreductase Polypeptides In force · High confidence | Codexis, Inc. | In force | High confidence | |
| US 9,657,320 | Engineered Ketoreductase Polypeptides In force · High confidence | Codexis, Inc. | In force | High confidence | |
| 16 more term ends in 2029 · Pro | |||||
10 of 26 patents shown. Soonest term end first, then patent number.
Pro members see all 26.
25 of these are in force and held by Codexis, Inc..
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.